Management of viral hepatitis in hematologic malignancies

Blood Reviews

Volumn 22, Issue 3, 2008, Pages 117-126

  Firpi, Roberto J ^a   Nelson, David R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Chemotherapy; Hematologic malignancies; Hepatitis B; Hepatitis C; Viral hepatitis

Indexed keywords

ADEFOVIR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOTOXIC AGENT; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; RIBAVIRIN; TELBIVUDINE;

ARTICLE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CYTOPENIA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; SURVIVAL TIME; VEIN OCCLUSION; VIRUS HEPATITIS; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; HEMATOLOGIC NEOPLASMS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; TRANSPLANTATION CONDITIONING;

EID: 41149117858     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.02.001     Document Type: Article

References (68)

1. Davis GL. Impact of HCV infection: Projections into the next century. 28[4], 390A. 1998. [abstract]. Hepatology 1998;28.
2. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
3. Yim H.J., and Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 (2006) S173-S181
4. Blackberg J., and Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 33 (2000) 992-997
5. Firpi R.J., and Martin P. Update on hepatitis B treatment. MedGenMed 4 (2002) 9
6. de FR, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J.Hepatol. 2003;39 Suppl 1:S3-25.:S3-25.
7. Kitano K., Kobayashi H., Hanamura M., et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 77 (2006) 255-258
8. Lubel J.S., Testro A.G., and Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37 (2007) 705-712
9. Hui C.K., Cheung W.W., Zhang H.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 (2006) 59-68
10. Lalazar G., Rund D., and Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136 (2007) 699-712
11. Nagington J. Reactivation of hepatitis b after transplantation operations. Lancet 1 (1977) 558-560
12. Nordbo S.A., Skaug K., Holter E., Waage A., and Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 65 (2000) 86-87
13. Steinberg J.L., Yeo W., Zhong S., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 60 (2000) 249-255
14. Xunrong L., Yan A.W., Liang R., and Lau G.K. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 11 (2001) 287-299
15. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299-307
16. Yeo W., and Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006) 209-220
17. Zekri A.R., Mohamed W.S., Samra M.A., et al. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 13 (2004) 305-311
18. Knoll A., Boehm S., Hahn J., Holler E., and Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33 (2004) 925-929
19. Kumagai K., Takagi T., Nakamura S., et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 8 Suppl 1 (1997) 107-109
20. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 (1991) 182-188
21. Zhong S., Yeo W., Schroder C., et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11 (2004) 55-59
22. Hui C.K., Lie A., Au W.Y., et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106 (2005) 464-469
23. Maguire C.M., Crawford D.H., Hourigan L.F., et al. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol 14 (1999) 801-803
24. Markovic S., Drozina G., Vovk M., and Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46 (1999) 2925-2930
25. Silvestri F., Sperotto A., Ermacora A., et al. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica. 85 (2000) 327-329
26. Ustun C., Koc H., Karayalcin S., et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 20 (1997) 289-296
27. Wong G.C., Tan P., Goh Y.T., et al. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 25 (1996) 500-503
28. Yagci M., Sucak G.T., and Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. Am J Hematol 64 (2000) 233-234
29. Yeo W., Steinberg J.L., Tam J.S., et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59 (1999) 263-269
30. Lau G.K., He M.L., Fong D.Y., et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36 (2002) 702-709
31. Martyak L.A., Taqavi E., and Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int (2007)
32. Yeo W., Chan P.K., Ho W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22 (2004) 927-934
33. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
34. Leung N.W., Tam J.S., Lau G.T., et al. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 73 (1994) 1143-1148
35. Onozawa M., Hashino S., Izumiyama K., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79 (2005) 616-619
36. Senecal D., Pichon E., Dubois F., et al. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 24 (1999) 1243-1244
37. Dreger P., Rautenberg P., Kneba M., and Schmitz N. Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC. Bone Marrow Transplant 26 (2000) 114-116
38. Iwai K., Tashima M., Itoh M., et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 25 (2000) 105-108
39. Dhedin N., Douvin C., Kuentz M., et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66 (1998) 616-619
40. Sekine R., Taketazu F., Kuroki M., et al. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int J Hematol 71 (2000) 256-258
41. McIvor C., Morton J., Bryant A., et al. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 121 (1994) 274-275
42. Dai M.S., Wu P.F., Shyu R.Y., Lu J.J., and Chao T.Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 24 (2004) 540-546
43. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 55 (2005) 828-831
44. Jang J.W., Choi J.Y., Bae S.H., et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43 (2006) 233-240
45. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
46. Li Y.H., He Y.F., Jiang W.Q., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106 (2006) 1320-1325
47. Yeo W., Ho W.M., Hui P., et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88 (2004) 209-215
48. Saab S., Dong M.H., Joseph T.A., and Tong M.J. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 46 (2007) 1049-1056
49. Hsiao L.T., Chiou T.J., Liu J.H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12 (2006) 84-94
50. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 (2000) 172-180
51. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
52. Perez-Roldan F., Gonzalez-Carro P., and Villafanez-Garcia M.C. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 352 (2005) 310-311
53. Cortelezzi A., Vigano M., Zilioli V.R., et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 35 (2006) 467-469
54. Fouillard L., Serfaty L., and Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 37 (2006) 625-626
55. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
56. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
57. Davis G.L. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 4 (2004) 7-17
58. Locasciulli A., Testa M., Valsecchi M.G., et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 68 (1999) 1486-1491
59. Peffault d.L., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103 (2004) 1618-1624
60. Ivantes C.A., Amarante H., Ioshii S.O., and Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 33 (2004) 1181-1185
61. Strasser S.I., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 29 (1999) 1893-1899
62. Strasser S.I., Sullivan K.M., Myerson D., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 93 (1999) 3259-3266
63. Zuckerman E., Zuckerman T., Douer D., Qian D., and Levine A.M. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 83 (1998) 1224-1230
64. Ribas A., and Gale R.P. Should people with hepatitis C virus infection receive a bone marrow transplant?. Bone Marrow Transplant 19 (1997) 97-99
65. Frickhofen N., Wiesneth M., Jainta C., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 83 (1994) 1998-2004
66. Gigliotti A.R., Fioredda F., and Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 25 (2003) 184-192
67. Ho V.T., Revta C., and Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant (2007)
68. Peffault de L.R., Asselah T., Levy V., et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 36 (2005) 709-713